Oasmia Pharmaceutical: Edison Open House Healthcare 2022

Oasmia Pharmaceutical: Edison Open House Healthcare 2022

Associated equity: Vivesto

Vivesto — 3 videos in collection

Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to develop novel formulations of well-established cytostatic oncology treatments for human and animal health. Key assets include Apealea (partnered with Elevar), docetaxel micellar and Cantrixil.

• Tell us about Oasmia and provide a high-level overview of its ongoing transformation.
• What can be expected from the imminent European launch of Apealea and what are your commercialisation plans?
• Please describe your ‘string of pearls’ strategy and how you are using it to build a diversified oncology portfolio.
• Please provide an update on the development of Cantrixil and the planned next steps, as well as on your other clinical asset, docetaxel micellar?
• Which milestones should investors focus on in the coming year?

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free